Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 121

1.

Emergency reversal of anticoagulation: novel agents.

Levine M, Goldstein JN.

Curr Neurol Neurosci Rep. 2014 Aug;14(8):471. doi: 10.1007/s11910-014-0471-7. Review.

PMID:
24969622
2.

Managing bleeding and emergency reversal of newer oral anticoagulants: a review for primary care providers.

Peacock WF.

Hosp Pract (1995). 2014 Oct;42(4):75-82. doi: 10.3810/hp.2014.10.1144.

PMID:
25502131
3.

Reversal of target-specific oral anticoagulants.

Siegal DM, Cuker A.

Drug Discov Today. 2014 Sep;19(9):1465-70. doi: 10.1016/j.drudis.2014.05.013. Epub 2014 May 29. Review.

4.

Laboratory monitoring of the non-vitamin K oral anticoagulants.

Blann AD, Lip GY.

J Am Coll Cardiol. 2014 Sep 16;64(11):1140-2. doi: 10.1016/j.jacc.2014.07.010. No abstract available.

5.

Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.

Cheng JW, Barillari G.

J Clin Pharm Ther. 2014 Apr;39(2):118-35. doi: 10.1111/jcpt.12122. Epub 2014 Jan 3. Review.

PMID:
24383983
6.

Bleeding Risk, Management and Outcome in Patients Receiving Non-VKA Oral Anticoagulants (NOACs).

Werth S, Breslin T, NiAinle F, Beyer-Westendorf J.

Am J Cardiovasc Drugs. 2015 Aug;15(4):235-42. doi: 10.1007/s40256-015-0123-6. Review. Erratum in: Am J Cardiovasc Drugs. 2015 Dec;15(6):451-2.

PMID:
25940651
7.

Direct Oral Anticoagulants (DOACs) in the Laboratory: 2015 Review.

Adcock DM, Gosselin R.

Thromb Res. 2015 Jul;136(1):7-12. doi: 10.1016/j.thromres.2015.05.001. Epub 2015 May 8. Review.

8.

Newer oral anticoagulants: a review of laboratory monitoring options and reversal agents in the hemorrhagic patient.

Miyares MA, Davis K.

Am J Health Syst Pharm. 2012 Sep 1;69(17):1473-84. doi: 10.2146/ajhp110725. Review. Erratum in: Am J Health Syst Pharm. 2012 Nov 15;69(22):1943.

PMID:
22899742
9.

Reversal of novel oral anticoagulants.

Abo-Salem E, Becker RC.

Curr Opin Pharmacol. 2016 Apr;27:86-91. doi: 10.1016/j.coph.2016.02.008. Epub 2016 Mar 2. Review.

PMID:
26939028
10.

Current state of knowledge on oral anticoagulant reversal using procoagulant factors.

Nitzki-George D, Wozniak I, Caprini JA.

Ann Pharmacother. 2013 Jun;47(6):841-55. doi: 10.1345/aph.1R724. Epub 2013 May 21. Review.

PMID:
23695644
11.

New oral anticoagulants: clinical indications, monitoring and treatment of acute bleeding complications.

Fenger-Eriksen C, Münster AM, Grove EL.

Acta Anaesthesiol Scand. 2014 Jul;58(6):651-9. doi: 10.1111/aas.12319. Epub 2014 Apr 9. Review.

PMID:
24716468
12.

Emerging anticoagulants.

Kennedy B, Gargoum FS, Kennedy L, Khan F, Curran DR, O'Connor TM.

Curr Med Chem. 2012;19(20):3388-416. Review.

PMID:
22680641
13.

Target-specific oral anticoagulants in patients undergoing cardioversion.

Law EH, Gordon W.

Am J Health Syst Pharm. 2014 Jul 15;71(14):1171-6. doi: 10.2146/ajhp130548. Review.

PMID:
24973374
14.

Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: proposals of the working group on perioperative haemostasis (GIHP) - March 2013.

Pernod G, Albaladejo P, Godier A, Samama CM, Susen S, Gruel Y, Blais N, Fontana P, Cohen A, Llau JV, Rosencher N, Schved JF, de Maistre E, Samama MM, Mismetti P, Sié P; Working Group on Perioperative Haemostasis.

Arch Cardiovasc Dis. 2013 Jun-Jul;106(6-7):382-93. doi: 10.1016/j.acvd.2013.04.009. Epub 2013 Jun 25.

15.

Oral and parenteral anticoagulants: new kids on the block.

Aditya S.

J Postgrad Med. 2012 Oct-Dec;58(4):275-85. doi: 10.4103/0022-3859.105448. Review.

16.

Stroke prevention in atrial fibrillation: impact of novel oral anticoagulants.

Haft JI.

Clin Appl Thromb Hemost. 2013 Jun;19(3):241-8. doi: 10.1177/1076029612458148. Epub 2012 Sep 4. Review.

PMID:
22952215
17.

Anticoagulation reversal in the era of the non-vitamin K oral anticoagulants.

Enriquez A, Lip GY, Baranchuk A.

Europace. 2016 Jul;18(7):955-64. doi: 10.1093/europace/euv030. Epub 2015 Mar 26. Review.

PMID:
25816811
18.

Oral anticoagulants and status of antidotes for the reversal of bleeding risk.

Ebright J, Mousa SA.

Clin Appl Thromb Hemost. 2015 Mar;21(2):105-14. doi: 10.1177/1076029614545211. Epub 2014 Aug 12. Review.

PMID:
25115762
19.

[Influence of NOACs on Thrombin Generation Assay].

Kawasugi K.

Rinsho Byori. 2014 Oct;62(10):965-9. Review. Japanese.

PMID:
27526542
20.

New anticoagulants (dabigatran, apixaban, rivaroxaban) for stroke prevention in atrial fibrillation.

Aguilar MI, Kuo RS, Freeman WD.

Neurol Clin. 2013 Aug;31(3):659-75. doi: 10.1016/j.ncl.2013.03.001. Review.

PMID:
23896498

Supplemental Content

Support Center